Anzeige
Mehr »
Login
Donnerstag, 15.04.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Top-Rendite fürs Depot: Superfood und Psychedelika-Medikamente!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 882807 ISIN: US92532F1003 Ticker-Symbol: VX1 
Tradegate
15.04.21
10:32 Uhr
180,96 Euro
-0,34
-0,19 %
1-Jahres-Chart
VERTEX PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
VERTEX PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
181,16182,3410:45
181,14182,4210:45

Aktuelle News zur VERTEX PHARMACEUTICALS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrVertex CEO Kewalramani collects $9.1M in 2020 pay, less than her biopharma peers34
FrThe numbers are in, and new Vertex CEO Reshma Kewalramani took home half of what predecessor Jeff Leiden did in his last year on the job15
29.03.Vertex: An Undervalued Business With A Promising Pipeline82
VERTEX PHARMACEUTICALS Aktie jetzt für 0€ handeln
26.03.Vertex Pharmaceuticals Incorporated: Vertex Receives CHMP Positive Opinion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat People With Cystic Fibrosis With At Least One F508del Mutation420If approved, people ages 12 years and older who have one copy of the F508del mutation and a gating (F/G) or residual function (F/RF) mutation will now be eligible for triple combination therapy -...
► Artikel lesen
25.03.Vertex Pharmaceuticals Incorporated: Vertex Receives Australian TGA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Treat People With Cystic Fibrosis Ages 12 Years and Older Who Have At Least One F508del Mutation461- With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)...
► Artikel lesen
23.03.Exclusive: Maze unveils their $191M pipeline, taking on Vertex and two long-sought conditions24
22.03.Vertex: Good Company, Fairly Valued46
18.03.Hot Stocks heute: Biotechs - Regeneron, Vertex Pharmaceuticals und Heidelberg Pharma1.567Im heutigen Podcast geht es um Biotech-Titel. Nach den Erfolgen von BioNTech zeigt sich, neue Technologien und Zulassungsverfahren führen zu einem Quantensprung in der Medikamenten-Forschung. Im finanzen.net...
► Artikel lesen
16.03.Vertex: 45% Upside Remains71
11.03.Vertex gains FDA fast track designation for diabetes stem cell therapy30
11.03.Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins19
11.03.Vertex Pharmaceuticals Incorporated: Vertex gibt Erteilung des Fast-Track-Status durch die FDA und Start der klinischen Phase-1/2-Studie zu VX-880 bekannt - eine neuartige Zelltherapie zur Behandlung von Typ-1-Diabetes1.030VX-880 ist die erste aus Stammzellen abgeleitete Prüftherapie mit vollständig differenzierten, Insulin produzierenden Pankreas-Inselzellen zur Behandlung von Typ-1-Diabetes - VX-880 ist die erste...
► Artikel lesen
10.03.Vertex snags fast-track tag for diabetes cell transplant picked up in $950M Semma buyout17
10.03.Grifols snags the rest of GigaGen in $80M acquisition; Vertex moves cutting-edge diabetes treatment into the clinic18
10.03.Vertex Reports FDA Fast Track Designation For VX-8801.017CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals Incorporated (VRTX) announced the FDA has granted Fast Track Designation for VX-880. VX-880, formerly known as STx-02, is an investigational...
► Artikel lesen
07.03.Barron's Latest Picks And Pans: Lowe's, Microsoft, Vertex Pharmaceuticals, ViacomCBS And More60
02.03.Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Presents at Cowen 41st Annual Health Care Conference (Transcript)40
20.02.What Should Vertex Pharmaceuticals Buy With its $6.6 Billion Stash?124
19.02.Here's Why Vertex Pharmaceuticals' Fourth Quarter Was Better Than It First Appeared109
19.02.Henry Skinner buys time in the fight against antimicrobial resistance; Vertex's Michael Parini becomes president and COO at Freeline while CFO Brian Silver plans his exit24
Seite:  Weiter >>
122 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
3,4,33